BioRestorative Therapies (BRTX) Q1 2024 Earnings

BRTX·Reported June 11, 2024·After market close

BioRestorative Therapies reported Q1 2024 revenue of $35.0K, beat analyst consensus of $30.0K by $5.0K. Diluted EPS came in at $-0.53, missed the $-0.51 consensus by $0.02.

Revenue

$35.0Kbeat by $5.0K

Consensus: $30.0K

Diluted EPS

$-0.53missed by $0.02

Consensus: $-0.51

SEC Filings

Earnings release8-K not filed yet

Quarterly report10-Q · 0001493152-24-023481

Financial Snapshot

Trailing eight quarters through Q1 2024

View all metrics

Revenue

Net Income

Operating Cash Flow

EPS (Diluted)

Q1 2024 Earnings FAQ

Common questions about BioRestorative Therapies's Q1 2024 earnings report.

BioRestorative Therapies (BRTX) reported Q1 2024 earnings on June 11, 2024 after market close.

BioRestorative Therapies reported revenue of $35.0K and diluted EPS of $-0.53 for Q1 2024.

Revenue beat the consensus estimate of $30.0K by $5.0K. EPS missed the consensus estimate of $-0.51 by $0.02.

You can read the 10-Q periodic report (0001493152-24-023481) directly on SEC EDGAR. The filing index links above go to sec.gov.